Literature DB >> 11080633

Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail.

L M Shewchuk1, A M Hassell, B Ellis, W D Holmes, R Davis, E L Horne, S H Kadwell, D D McKee, J T Moore.   

Abstract

BACKGROUND: Angiogenesis, the formation of new vessels from the existing vasculature, is a critical process during early development as well as in a number of disease processes. Tie2 (also known as Tek) is an endothelium-specific receptor tyrosine kinase involved in both angiogenesis and vasculature maintenance.
RESULTS: We have determined the crystal structure of the Tie2 kinase domain to 2.2 A resolution. The structure contains the catalytic core, the kinase insert domain (KID), and the C-terminal tail. The overall fold is similar to that observed in other serine/threonine and tyrosine kinase structures; however, several unique features distinguish the Tie2 structure from those of other kinases. The Tie2 nucleotide binding loop is in an inhibitory conformation, which is not seen in other kinase structures, while its activation loop adopts an "activated-like" conformation in the absence of phosphorylation. Tyr-897, located in the N-terminal domain, may negatively regulate the activity of Tie2 by preventing dimerization of the kinase domains or by recruiting phosphatases when it is phosphorylated.
CONCLUSION: Regulation of the kinase activity of Tie2 is a complex process. Conformational changes in the nucleotide binding loop, activation loop, C helix, and the C-terminal tail are required for ATP and substrate binding.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11080633     DOI: 10.1016/s0969-2126(00)00516-5

Source DB:  PubMed          Journal:  Structure        ISSN: 0969-2126            Impact factor:   5.006


  32 in total

1.  Common and specific effects of TIE2 mutations causing venous malformations.

Authors:  Marjut Nätynki; Jaakko Kangas; Ilkka Miinalainen; Raija Sormunen; Riikka Pietilä; Julie Soblet; Laurence M Boon; Miikka Vikkula; Nisha Limaye; Lauri Eklund
Journal:  Hum Mol Genet       Date:  2015-08-28       Impact factor: 6.150

2.  Autoinhibition of the insulin-like growth factor I receptor by the juxtamembrane region.

Authors:  Barbara P Craddock; Christopher Cotter; W Todd Miller
Journal:  FEBS Lett       Date:  2007-06-19       Impact factor: 4.124

3.  A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution.

Authors:  Douglas S Auld; Ya-Qin Zhang; Noel T Southall; Ganesha Rai; Marc Landsman; Jennifer MacLure; Daniel Langevin; Craig J Thomas; Christopher P Austin; James Inglese
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

Review 4.  Overview of protein structural and functional folds.

Authors:  Peter D Sun; Christine E Foster; Jeffrey C Boyington
Journal:  Curr Protoc Protein Sci       Date:  2004-05

5.  Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects.

Authors:  Vinciane Wouters; Nisha Limaye; Melanie Uebelhoer; Alexandre Irrthum; Laurence M Boon; John B Mulliken; Odile Enjolras; Eulalia Baselga; Jonathan Berg; Anne Dompmartin; Sten A Ivarsson; Loshan Kangesu; Yves Lacassie; Jill Murphy; Ahmad S Teebi; Anthony Penington; Paul Rieu; Miikka Vikkula
Journal:  Eur J Hum Genet       Date:  2009-11-04       Impact factor: 4.246

6.  A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases.

Authors:  Huaibin Chen; Jinghong Ma; Wanqing Li; Anna V Eliseenkova; Chongfeng Xu; Thomas A Neubert; W Todd Miller; Moosa Mohammadi
Journal:  Mol Cell       Date:  2007-09-07       Impact factor: 17.970

7.  EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism.

Authors:  G Pines; P H Huang; Y Zwang; F M White; Y Yarden
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

8.  Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations.

Authors:  Nisha Limaye; Vinciane Wouters; Melanie Uebelhoer; Marjut Tuominen; Riikka Wirkkala; John B Mulliken; Lauri Eklund; Laurence M Boon; Miikka Vikkula
Journal:  Nat Genet       Date:  2008-12-14       Impact factor: 38.330

9.  Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects.

Authors:  Elisa Boscolo; Nisha Limaye; Lan Huang; Kyu-Tae Kang; Julie Soblet; Melanie Uebelhoer; Antonella Mendola; Marjut Natynki; Emmanuel Seront; Sophie Dupont; Jennifer Hammer; Catherine Legrand; Carlo Brugnara; Lauri Eklund; Miikka Vikkula; Joyce Bischoff; Laurence M Boon
Journal:  J Clin Invest       Date:  2015-08-10       Impact factor: 14.808

10.  VE-PTP controls blood vessel development by balancing Tie-2 activity.

Authors:  Mark Winderlich; Linda Keller; Giuseppe Cagna; Andre Broermann; Olena Kamenyeva; Friedemann Kiefer; Urban Deutsch; Astrid F Nottebaum; Dietmar Vestweber
Journal:  J Cell Biol       Date:  2009-05-18       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.